BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 38530703)

  • 21. Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
    Osko JD; Christianson DW
    Acta Crystallogr F Struct Biol Commun; 2020 Sep; 76(Pt 9):428-437. PubMed ID: 32880591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of histone deacetylase 3 by metal cations and 10-hydroxy-2E-decenoic acid: Possible epigenetic mechanisms of queen-worker bee differentiation.
    Polsinelli GA; Yu HD
    PLoS One; 2018; 13(12):e0204538. PubMed ID: 30532259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.
    Montero A; Beierle JM; Olsen CA; Ghadiri MR
    J Am Chem Soc; 2009 Mar; 131(8):3033-41. PubMed ID: 19239270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
    Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA
    Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Zinc-dependent HDACs: Non-histone Substrates and Catalytic Deacylation Beyond Deacetylation.
    Zheng W
    Mini Rev Med Chem; 2022; 22(19):2478-2485. PubMed ID: 35362374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11.
    Madsen AS; Kristensen HM; Lanz G; Olsen CA
    ChemMedChem; 2014 Mar; 9(3):614-26. PubMed ID: 24375963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.
    Porter NJ; Wagner FF; Christianson DW
    Biochemistry; 2018 Jul; 57(26):3916-3924. PubMed ID: 29775292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.
    Hyndman KA
    Semin Nephrol; 2020 Mar; 40(2):138-147. PubMed ID: 32303277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
    Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
    J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells.
    Lee JH; Jeong EG; Choi MC; Kim SH; Park JH; Song SH; Park J; Bang YJ; Kim TY
    Mol Cells; 2010 Aug; 30(2):107-12. PubMed ID: 20680488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation of a new construct of human histone deacetylase 8 for the crystallization of enzyme-inhibitor complexes.
    Porter NJ; Christianson DW
    Methods Enzymol; 2019; 626():561-585. PubMed ID: 31606091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring structural requirements of HDAC10 inhibitors through comparative machine learning approaches.
    Bhattacharya A; Amin SA; Kumar P; Jha T; Gayen S
    J Mol Graph Model; 2023 Sep; 123():108510. PubMed ID: 37216830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel class of small molecule inhibitors of HDAC6.
    Inks ES; Josey BJ; Jesinkey SR; Chou CJ
    ACS Chem Biol; 2012 Feb; 7(2):331-9. PubMed ID: 22047054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases.
    Schultz BE; Misialek S; Wu J; Tang J; Conn MT; Tahilramani R; Wong L
    Biochemistry; 2004 Aug; 43(34):11083-91. PubMed ID: 15323567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical and structural biology of protein lysine deacetylases.
    Yoshida M; Kudo N; Kosono S; Ito A
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(5):297-321. PubMed ID: 28496053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
    Osko JD; Christianson DW
    Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiling of substrates for zinc-dependent lysine deacylase enzymes: HDAC3 exhibits decrotonylase activity in vitro.
    Madsen AS; Olsen CA
    Angew Chem Int Ed Engl; 2012 Sep; 51(36):9083-7. PubMed ID: 22890609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.